Cargando…

Combination therapy using GDNF and cell transplant in Parkinson’s disease

Detalles Bibliográficos
Autores principales:	Xiao, Bin, Zhang, Su-Chun, Tan, Eng-King
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research Highlight
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9288671/ https://www.ncbi.nlm.nih.gov/pubmed/35842673 http://dx.doi.org/10.1186/s13024-022-00553-9

Ejemplares similares

Neurotrophic factor therapy for Parkinson's disease: past, present and future
por: Sullivan, Aideen M., et al.
Publicado: (2016)

The Future of GDNF in Parkinson's Disease
por: Manfredsson, Fredric P., et al.
Publicado: (2020)

GDNF-based therapies, GDNF-producing interneurons, and trophic support of the dopaminergic nigrostriatal pathway. Implications for Parkinson’s disease
por: d’Anglemont de Tassigny, Xavier, et al.
Publicado: (2015)

Using Extracellular Vesicles Released by GDNF-Transfected Macrophages for Therapy of Parkinson Disease
por: Zhao, Yuling, et al.
Publicado: (2022)

First stem cell transplantation to regenerate human lung
por: Wang, Si, et al.
Publicado: (2018)

Breathing new life into an old target: pulmonary disease drugs for Parkinson’s disease therapy
por: Abdelmotilib, Hisham, et al.
Publicado: (2017)

Advances in Liver Transplantation: where are we in the pursuit of transplantation tolerance?
por: Safinia, Niloufar, et al.
Publicado: (2021)

Cell replacement for Parkinson’s disease: advances and challenges
por: Xiao, Bin, et al.
Publicado: (2023)

The emerging roles of transplanted radial glial cells in regenerating the central nervous system
por: White, Robin E., et al.
Publicado: (2015)

Non-toxic HSC Transplantation-Based Macrophage/Microglia-Mediated GDNF Delivery for Parkinson’s Disease
por: Chen, Cang, et al.
Publicado: (2019)

Versatile guardians: regenerative regulatory T cells in Parkinson’s disease rodent models
por: Ip, Chi Wang, et al.
Publicado: (2023)

Targeting LRRK2 in Parkinson’s disease
por: Xiao, Bin, et al.
Publicado: (2022)

Immunotherapy trials in Parkinson’s disease: challenges
por: Xiao, Bin, et al.
Publicado: (2023)

Effects of striatal transplantation of cells transfected with GDNF gene without pre- and pro-regions in mouse model of Parkinson’s disease
por: Revishchin, A., et al.
Publicado: (2016)

Pre-α-pro-GDNF and Pre-β-pro-GDNF Isoforms Are Neuroprotective in the 6-hydroxydopamine Rat Model of Parkinson's Disease
por: Penttinen, Anna-Maija, et al.
Publicado: (2018)

Sinoatrial node pacemaker cells: cardiomyocyte- or neuron-like cells?
por: Zhou, Bin
Publicado: (2021)

Mitochondrial Complex I deficiency: guilty in Parkinson’s disease
por: Vos, Melissa
Publicado: (2022)

Potential mechanisms by which impaired ketogenesis links metabolism to T‐cell dysfunction in patients with severe COVID‐19
por: Wang, Bin, et al.
Publicado: (2022)

Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2022 Update
por: McFarthing, Kevin, et al.
Publicado: (2022)

Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2023 Update
por: McFarthing, Kevin, et al.
Publicado: (2023)

On the road to epigenetic therapy
por: Walton, Emma L.
Publicado: (2016)

Dental pulp stem cells for treating neurodegenerative diseases
por: Shamir, Christopher, et al.
Publicado: (2015)

Combination therapy for HCC: from CRISPR screening to the design of clinical therapies
por: Wang, Yunguang, et al.
Publicado: (2021)

Regulatory T cell metabolism at the intersection between autoimmune diseases and cancer
por: Kurniawan, Henry, et al.
Publicado: (2020)

Regulatory T cells as a therapeutic approach for inflammatory bowel disease
por: Laukova, Marcela, et al.
Publicado: (2023)

Who Has Therapy-Related AML?
por: Gale, Robert Peter, et al.
Publicado: (2017)

Towards gene therapy for IPEX syndrome
por: Borna, Simon, et al.
Publicado: (2022)

Biological implications and limitations of a cynomolgus monkey with naturally occurring Parkinson’s disease
por: Li, Hao, et al.
Publicado: (2021)

Targeting B cells and plasma cells in autoimmune diseases: From established treatments to novel therapeutic approaches
por: Merino‐Vico, Ana, et al.
Publicado: (2022)

Development of Antibody‐Directed Therapies: Quo Vadis?
por: Rodrigues, Tiago, et al.
Publicado: (2018)

Bi-Atom Electrocatalyst for Electrochemical Nitrogen Reduction Reactions
por: Zhang, Wenchao, et al.
Publicado: (2021)

Kidney injury molecule-1: a novel entry factor for SARS-CoV-2
por: Wan, Cheng, et al.
Publicado: (2021)

Modulating serine palmitoyltransferase‐deoxysphingolipid axis in cancer therapy
por: Xiang, Yuancai, et al.
Publicado: (2020)

Mitophagy and reactive oxygen species interplay in Parkinson’s disease
por: Xiao, Bin, et al.
Publicado: (2022)

Circular RNA vaccine, a novel mRNA vaccine design strategy for SARS‐CoV‐2 and variants
por: Su, Peng, et al.
Publicado: (2022)

In vivo activation of transferred regulatory T cells specific for third‐party exogenous antigen controls GVH disease in mice
por: Martin, Gaëlle H., et al.
Publicado: (2013)

Genetic tracing of HCoV-19 for the re-emerging outbreak of COVID-19 in Beijing, China
por: Yang, Jing, et al.
Publicado: (2020)

Increased antiparkinson efficacy of the combined administration of VEGF- and GDNF-loaded nanospheres in a partial lesion model of Parkinson’s disease
por: Herrán, Enara, et al.
Publicado: (2014)

Induced pluripotent stem cells in Parkinson's disease: scientific and clinical challenges
por: Xiao, Bin, et al.
Publicado: (2016)

Antigen‐presenting cells maintain T cells proliferation through vesicle transfer of telomeres: A new approach to telomere extension
por: Zhang, Xiaorui, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lqsn6d9noinrdbo3igd75smlvr